Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd. (NVCR)
NASDAQ:NVCR
Earnings Data
Report Date
Apr 23, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.31Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of strong commercial and clinical progress (record revenue, meaningful active patient growth, FDA approval of Optune Pax, upcoming trial readouts, improved non‑GBM revenue trajectory, solid cash position and convertible note repayment) alongside near‑term profitability and operational challenges (net losses and negative adjusted EBITDA, gross margin compression, increased R&D spend, slower Optune Lua launch, reimbursement timing for Optune Pax, and a resolved Medicare administrative issue). Management provided formal 2026 guidance (revenue growth of 3%–8% and adjusted EBITDA of negative $20 million to breakeven), signifying a clear path toward stabilizing growth and driving to profitability while acknowledging near‑term execution and reimbursement risks.Company Guidance
Record Revenue and Year‑Over‑Year Growth
Full‑year net revenue of $655 million and fourth quarter net revenue of $174 million, each representing 8% year‑over‑year growth versus 2024.
Strong Active Patient Growth in Key International Markets
Notable active patient growth ex‑U.S.: Germany +10% YoY, France +19% YoY, Japan +29% YoY; U.S. active patients grew +4% YoY.
FDA Approval of Optune Pax with Rapid Review
Optune Pax approved Feb 11 for locally advanced pancreatic cancer (first‑line with nab‑paclitaxel + gemcitabine); FDA review completed at the 180‑day mark (faster than typical 9–12 month PMA timeline). U.S. launch has commenced and filings submitted in EU and Japan.
Pipeline and Clinical Catalysts Upcoming
Presented final data from two large randomized trials and published in major journals; PMA submissions for pancreatic cancer and brain metastases in place. Top‑line readouts expected: PANOVA‑4 next month, TRIDENT in Q2, and KEYNOTE‑58 Phase III enrollment expected complete by year‑end.
Growing Non‑GBM Revenue Trajectory
Optune Lua revenue totaled $10.4 million for 2025 (including $5.8 million from NSCLC); Q4 Optune Lua recognition $3.5 million (including $2.4 million for NSCLC). Company expects non‑GBM contributions of $15 million–$25 million in 2026 vs $10 million in 2025.
Solid Liquidity and Debt Reduction
Cash and investments of $448 million at year‑end and repayment of $561 million of convertible notes in Q4. Only $200 million drawn on the credit facility and management does not plan additional draws, providing runway while new revenue streams ramp.
First Formal Guidance and Path to Profitability
Issued 2026 revenue guidance of $675 million–$705 million (3%–8% YoY growth at constant FX) and adjusted EBITDA guidance of negative $20 million to breakeven, signaling a clear objective to reach adjusted EBITDA breakeven in 2026.
Cost Discipline and Operating Efficiency Signals
Full‑year sales & marketing expense flat at $240 million YoY and Q4 G&A down 41% (Q4 $43 million) with full‑year G&A down 6% to $178 million, driven by lower share‑based compensation in the period.
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $14.99 | $13.75 | -8.27% |
Oct 30, 2025 | $13.48 | $12.82 | -4.90% |
Jul 24, 2025 | $16.51 | $12.54 | -24.05% |
Apr 24, 2025 | $17.77 | $18.55 | +4.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NovoCure Ltd. (NVCR) report earnings?
NovoCure Ltd. (NVCR) is schdueled to report earning on Apr 23, 2026, TBA (Confirmed).
What is NovoCure Ltd. (NVCR) earnings time?
NovoCure Ltd. (NVCR) earnings time is at Apr 23, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2026 (Q1) is -0.49.